Anticoagulation Monitoring
Section snippets
Discovery of heparin and vitamin K antagonists
The discoveries of heparin and VKAs are fascinating glimpses into the scientific practices and larger cultural backdrops of the associated historical times. The discovery of heparin was steeped in controversy, with multiple scientists claiming credit.4, 5 Furthermore, reading the original description of its early crude preparations, made from autolyzing bovine liver, evokes vivid pungent and visceral reactions even today.5
The discovery of warfarin reads like a Horatio Alger success story.4, 5, 6
Warfarin–vitamin K antagonist therapy: use the international normalized ratio to monitor
Warfarin's mechanism of anticoagulation action is by inhibiting gamma carboxylation of the vitamin K–dependent coagulation factors. This results in a decreased level of active coagulation factors and an excess of precursor coagulation factors, or proteins induced by VKAs.
The demonstration of warfarin's effectiveness early in its development was hampered by highly variable laboratory assays. The development of the international normalized ratio (INR) system in the mid-1980s helped reduce
Point-of-care testing international normalized ratio accuracy and reproducibility
Significant INR variability has been demonstrated within the controlled environment of a clinical laboratory. With point-of-care testing (POCT), additional test reliability concerns arose, most notably related to personnel competency and test environment (ie, temperature, humidity).19, 20 In recognition of these additional concerns associated with POCT, two key questions were posed when POCT INR test devices became commercially available: how do INRs generated from POCT devices compare with
Heparins
Heparin is a negatively charged glycosaminoglycan comprised of repeating sulfated disaccharide units (Fig. 4) derived from animal or plant sources. Heparin has been used for treatment for almost a century; the reader is referred to the many excellent reviews on this subject for more detail.37, 38, 39, 40
Laboratory testing to monitor unfractionated heparin anticoagulant effect
Review of the intrinsic pathway of coagulation demonstrates the multiple points at which UFH blocks clotting, with corresponding prolongation of the activated PTT. The major UFH effect on PTT prolongation is, however, directly caused by inhibition of thrombin activity.
Early in its clinical use, PTT was advocated as the preferred laboratory test for establishing the patient had achieved the desired therapeutic range, and sequential PTT determinations to ensure the patient maintained the desired
Direct FXa inhibitors (xabans)
There is limited information on oral direct FXa inhibitors, because many are in the midst of clinical trials and no definitive statement can be made regarding their clinical applicability.67
Two xabans (rivaroxaban and apixaban) have received the most attention. Both have excellent bioavailability, predictable pharmacokinetics, are taken orally, bind reversibly to FXa, and have plasma half-lives of many hours. They differ in metabolism; rivaroxaban is excreted renally, whereas apixaban is
Direct thrombin inhibitors
Thrombin plays a central role in hemostasis, acting at multiple points in the clotting cascade.38, 39, 40 It has both prothrombotic (ie, cleavage of fibrinogen to fibrin to start clot formation, activation of FXIII, platelet activation, and inhibition of fibrinolysis by a thrombin-activatable fibrinolysis inhibitor) and anticoagulant (ie, protein C activation) effects, and effects on endothelium and vascular smooth muscle cells.38, 39, 40 Thrombin itself is inhibited by AT and this interaction
Summary
This is a dissatisfying end to an exciting time in clinical anticoagulant therapy. With the exception of the INR for monitoring patients on chronic warfarin therapy, any other coagulation test used to monitor any other anticoagulant suffers from a lack of standardization and the presence of significant variability of results depending on which reagent or test method is used.
For the laboratorian, caveat emptor. It is absolutely critical to know how the assay performs with the target patient
References (76)
- et al.
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)
Chest
(2008) - et al.
Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)
Chest
(2008) - et al.
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)
Chest
(2008) - et al.
Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)
Chest
(2008) - et al.
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest
(2008) - et al.
Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation
Thromb Res
(2004) - et al.
International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?
Ann Thorac Surg
(2001) - et al.
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
(2004) - et al.
Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents
Thromb Res
(2007) - et al.
Apparent heparin resistance from elevated factor VIII during pregnancy
Obstet Gynecol
(2000)
Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children
Thromb Res
Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing
Clin Chim Acta
Beyond unfractionated heparin and warfarin: current and future advances
Circulation
Heterogeneity of synthetic factor Xa inhibitors
Curr Pharm Des
Direct thrombin inhibitors
N Engl J Med
The oral anticoagulant saga: past, present, and future
Clin Appl Thromb Hemost
The story of the discovery of heparin and warfarin
Br J Haematol
The discovery of dicumarol and its sequels
Circulation
Falsely elevated INR results due to the sensitivity of a thromboplastin reagent to heparin
Am J Clin Pathol
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose
PLoS Genet
International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements
Clin Chem
Procedures for validation of INR and local calibration of PT/INR systems; approved guideline
Failure of the international normalized ratio to generate consistent results within a local medical community
Am J Clin Pathol
Highly sensitive thromboplastins do not improve INR precision
Am J Clin Pathol
Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system
Haematologica
Coagulation limited. Participant summary
QC for the future: laboratory issues - POCT and POL concerns
Lab Med
My three wishes for point-of-care testing
Journal of Point-of-Care Testing
Point-of-care prothrombin time measurement for professional and patient self-testing use. A multicenter clinical experience. Oral Anticoagulation Monitoring Study Group
Am J Clin Pathol
European concerted action on anticoagulation: use of plasma samples to derive international sensitivity index for whole-blood prothrombin time monitors
Clin Chem
A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors
Am J Clin Pathol
Point-of-care international normalised ratios: UK NEQAS experience demonstrates necessity for proficiency testing of three different monitors
Thromb Haemost
Standard QC.1.80
Point of care testing inspection checklist item POC.07568
Centers for Disease Control and Prevention. 493.1253 Standard; Establishment and verification of method performance specifications
Medical laboratories: particular requirements for quality and competence
C54-A. Verification of comparability of patient results within one health care system; approved guideline
Clinical impact of point-of-care vs laboratory measurement of anticoagulation
Am J Clin Pathol
Cited by (13)
Antithrombotic therapies and their laboratory assessment
2019, Rodak’s Hematology: Clinical Principles and ApplicationsAnticoagulants: Newer ones, mechanisms, and perioperative updates
2010, Anesthesiology ClinicsCitation Excerpt :Dabigatran, like argatroban, is a synthetic small-molecule hirudin analog. It exhibits univalent binding to only one of the two key thrombin sites.16 Dabigatran etexilate is the prodrug of dabigatran, a reversible inhibitor of the active site of thrombin.
Nonfatal self-poisoning with LMW heparin and the use of antidote
2010, Thrombosis ResearchPharmacology of anticoagulants used in the treatment of venous thromboembolism
2016, Journal of Thrombosis and ThrombolysisThrombosis
2013, Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of DrugsEffect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirement in South Indian population
2013, Indian Journal of Physiology and Pharmacology